Skip to main content
Erschienen in: Lung 3/2016

29.04.2016

Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population

verfasst von: Qing-Feng Liu, Zhi-Fei Zhang, Guang-Jie Hou, Guang-Yu Yang, Yi He

Erschienen in: Lung | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

To explore the association of functional single-nucleotide polymorphisms (SNPs) of CD133 with the risk of lung cancer.

Methods

We conducted a hospital-based, case–control study of 1017 lung cancer patients and 1035 cancer-free controls frequency-matched by age and sex. Four functional CD133 SNPs (rs2240688 A > C, rs10022537 T > A, rs7686732 C > G, and rs3130 C > T) were selected and genotyped. Unconditional univariate and multivariate logistic regression analyses were carried out to evaluate the associations of genotypes of CD133 SNPs with lung cancer risk.

Results

Compared with rs2240688 AA genotype, the variant AC/CC genotypes were associated with a statistically increased risk of lung cancer under a recessive model (adjusted odds ratio 1.19; 95 % confidence interval 1.01–1.42). The risk remained in patients with other histology types, but not with adenocarcinoma and squamous cell cancers.

Conclusions

These findings suggest that SNP rs2240688 A > C of CD133 may be a potential biomarker for genetic susceptibility to lung cancer, but require further research with larger populations.
Literatur
9.
Zurück zum Zitat Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12):5002–5012PubMed Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90(12):5002–5012PubMed
11.
Zurück zum Zitat Abols A, Ducena K, Zayakin P et al (2014) Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomark 14(5):361–369. doi:10.3233/CBM-140413 PubMed Abols A, Ducena K, Zayakin P et al (2014) Survey of autoantibody responses against tumor-associated antigens in thyroid cancer. Cancer Biomark 14(5):361–369. doi:10.​3233/​CBM-140413 PubMed
16.
Zurück zum Zitat Pohl A, El-Khoueiry A, Yang D et al (2013) Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 13(2):173–180. doi:10.1038/tpj.2011.61 CrossRefPubMedPubMedCentral Pohl A, El-Khoueiry A, Yang D et al (2013) Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J 13(2):173–180. doi:10.​1038/​tpj.​2011.​61 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4(1):32–42PubMedPubMedCentral Woo T, Okudela K, Mitsui H et al (2010) Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4(1):32–42PubMedPubMedCentral
18.
Zurück zum Zitat Cheng M, Yang L, Yang R et al (2013) A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis 34(10):2292–2299. doi:10.1093/carcin/bgt181 CrossRefPubMed Cheng M, Yang L, Yang R et al (2013) A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis 34(10):2292–2299. doi:10.​1093/​carcin/​bgt181 CrossRefPubMed
19.
Zurück zum Zitat Wang Q, Liu H, Xiong H et al (2015) Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog 54(6):449–458. doi:10.1002/mc.22113 CrossRefPubMed Wang Q, Liu H, Xiong H et al (2015) Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. Mol Carcinog 54(6):449–458. doi:10.​1002/​mc.​22113 CrossRefPubMed
20.
Zurück zum Zitat Okudela K, Woo T, Mitsui H et al (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma—their prognostic significance. Pathol Int 62(12):792–801. doi:10.1111/pin.12019 CrossRefPubMed Okudela K, Woo T, Mitsui H et al (2012) Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma—their prognostic significance. Pathol Int 62(12):792–801. doi:10.​1111/​pin.​12019 CrossRefPubMed
21.
Zurück zum Zitat Corbeil D, Roper K, Fargeas CA et al (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2(2):82–91CrossRefPubMed Corbeil D, Roper K, Fargeas CA et al (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2(2):82–91CrossRefPubMed
23.
Zurück zum Zitat Hu Z, Wu C, Shi Y et al (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43(8):792–796. doi:10.1038/ng.875 CrossRefPubMed Hu Z, Wu C, Shi Y et al (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43(8):792–796. doi:10.​1038/​ng.​875 CrossRefPubMed
Metadaten
Titel
Polymorphisms of the Stem Cell Marker Gene CD133 and the Risk of Lung Cancer in Chinese Population
verfasst von
Qing-Feng Liu
Zhi-Fei Zhang
Guang-Jie Hou
Guang-Yu Yang
Yi He
Publikationsdatum
29.04.2016
Verlag
Springer US
Erschienen in
Lung / Ausgabe 3/2016
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9876-1

Weitere Artikel der Ausgabe 3/2016

Lung 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.